Failure of human fibroblast interferon to protect against rhinovirus infection.
Volunteers were treated with fibroblast interferon or placebo nose drops for four days. On the second day, they received a challenge with rhinovirus type 4. There was no difference in the clinical symptoms or viral shedding between the two groups. The possible reasons for this result are discussed.
D000281:Administration, Intranasal; D002986:Clinical Trials as Topic; D003139:Common Cold / Q000517:prevention & control*; D005260:Female; D005347:Fibroblasts; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D009297:Nasal Mucosa / Q000382:microbiology; D010919:Placebos; D012229:Rhinovirus / Q000302:isolation & purification
D010919:Placebos; D007372:Interferons